HK1256935A1 - 使用疫苗治疗癌症或皮肤病变的方法和组合物 - Google Patents

使用疫苗治疗癌症或皮肤病变的方法和组合物 Download PDF

Info

Publication number
HK1256935A1
HK1256935A1 HK18116062.9A HK18116062A HK1256935A1 HK 1256935 A1 HK1256935 A1 HK 1256935A1 HK 18116062 A HK18116062 A HK 18116062A HK 1256935 A1 HK1256935 A1 HK 1256935A1
Authority
HK
Hong Kong
Prior art keywords
hpv
dose
vaccine
patient
cancer
Prior art date
Application number
HK18116062.9A
Other languages
English (en)
Chinese (zh)
Inventor
蒂姆‧艾恩尼德斯
Original Assignee
哈普威克斯有限责任公司
哈普威克斯有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 哈普威克斯有限责任公司, 哈普威克斯有限責任公司 filed Critical 哈普威克斯有限责任公司
Publication of HK1256935A1 publication Critical patent/HK1256935A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
HK18116062.9A 2016-02-27 2017-02-24 使用疫苗治疗癌症或皮肤病变的方法和组合物 HK1256935A1 (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US62/300,785 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US62/328,487 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US62/338,183 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US62/444,576 2017-01-10
US201762455434P 2017-02-06 2017-02-06
US62/455,434 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
HK1256935A1 true HK1256935A1 (zh) 2019-10-04

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116062.9A HK1256935A1 (zh) 2016-02-27 2017-02-24 使用疫苗治疗癌症或皮肤病变的方法和组合物

Country Status (16)

Country Link
EP (1) EP3419661A4 (https=)
JP (3) JP2019506435A (https=)
KR (1) KR102873848B1 (https=)
CN (1) CN108883168A (https=)
AU (1) AU2017223970B2 (https=)
BR (1) BR112018067550A2 (https=)
CA (1) CA3015519A1 (https=)
CL (1) CL2018002438A1 (https=)
CO (1) CO2018009205A2 (https=)
HK (1) HK1256935A1 (https=)
IL (1) IL261340B2 (https=)
MX (1) MX2018010338A (https=)
MY (1) MY194694A (https=)
SG (1) SG11201807080UA (https=)
WO (1) WO2017147475A1 (https=)
ZA (1) ZA201805679B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
PL4225351T1 (pl) * 2020-10-12 2023-12-11 Hpvvax, Llc Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym
WO2024097051A1 (en) * 2022-10-31 2024-05-10 Pyrojas Inc. Immunotherapy compositions and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP3427755B1 (en) * 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
SG177269A1 (en) * 2009-06-25 2012-02-28 Glaxosmithkline Biolog Sa Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9974849B2 (en) * 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine
JP7037884B2 (ja) * 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗

Also Published As

Publication number Publication date
IL261340B1 (en) 2023-03-01
EP3419661A4 (en) 2019-10-23
KR102873848B1 (ko) 2025-10-17
JP2023110038A (ja) 2023-08-08
BR112018067550A2 (pt) 2019-10-01
AU2017223970B2 (en) 2022-01-27
EP3419661A1 (en) 2019-01-02
JP2019506435A (ja) 2019-03-07
CO2018009205A2 (es) 2018-09-20
MY194694A (en) 2022-12-15
JP2021155448A (ja) 2021-10-07
MX2018010338A (es) 2018-11-09
ZA201805679B (en) 2019-11-27
AU2017223970A1 (en) 2018-09-13
WO2017147475A1 (en) 2017-08-31
CL2018002438A1 (es) 2019-01-04
JP7732784B2 (ja) 2025-09-02
KR20180112043A (ko) 2018-10-11
CA3015519A1 (en) 2017-08-31
CN108883168A (zh) 2018-11-23
IL261340A (en) 2018-11-29
IL261340B2 (en) 2023-07-01
SG11201807080UA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
US20240245690A1 (en) Treatment of Respiratory Diseases
JP2023110038A (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
AU2023204000A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
CN109562281A (zh) 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
CA3219273A1 (en) Use of 5-nitro-8-hydroxyquinoline
US10799574B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
AU2021360676B2 (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
WO2021221537A1 (ru) Противо-sars-cov-2 вирусное средство антипровир
WO2021221532A1 (ru) Противо-sars-cov-2 вирусное средство антипровир
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
CN118948873B (zh) 金线莲苷在防治脑胶质瘤中的应用
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита
US20210346459A1 (en) Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs
HK40111065A (zh) 使用药物和疫苗接种组合治疗的用於治疗、改善或预防感染的方法
US20230310467A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
CN106955280A (zh) 一种防治副猪嗜血杆菌病的药物及其应用
CN107001430A (zh) 癌症和皮肤病变治疗
HK40058742A (en) Treatment of respiratory diseases
KR20060123329A (ko) 월경 곤란증의 예방 및/또는 치료제
CN101247802A (zh) 抑制、破坏和/或灭活病毒的方法和组合物
KR20060120204A (ko) 삼출성 중이염의 예방 및/또는 치료제